The Outcome of SARS-CoV-2 Infection in Patients with Lymphoma and the Risk Factors for the Development of Pneumonia
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background Although patients with lymphoma appear particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the clinical evolution of coronavirus disease 2019 (COVID-19) in a patient with lymphoid malignancies has been under-represented, especially in relation to chemo-, chemo-immunotherapy. Materials and Methods Among adult patients with lymphoma receiving treatment in a specialized lymphoma center at a 500-bed, university-affiliated hospital, we retrospectively reviewed the medical records of patients diagnosed with SARS-CoV-2 infection from January 2020 to April 2022. Results A total of 117 patients with a median age of 53 years were included. One hundred twelves (95.7%) were non-Hodgkin lymphoma. Eighty-six patients (73.5%) were on active chemotherapy and 9 were post stem cell transplant state. Sixty-one patients had more than one comorbidity and 29 had hypogammaglobulinemia. Thirty-four patients (29.1%) had never received a COVID-19 vaccine. During a median follow-up of 134 days, COVID-19 pneumonia developed in 37 patients (31.6%). Excluding three patients who died before the 30 days, 31 out of 34 patients had ongoing symptomatic COVID-19. Eleven patients (9.4%) had post COVID-19 lung condition that persisted 90 days after COVID-19 diagnosis. Overall mortality was 10.3% (12 of 117), which was higher in patients with pneumonia. In multivariate analyses, age 65 years or older, follicular lymphoma, receiving rituximab maintenance therapy, and lack of vaccination were significantly associated with the development of COVID-19 pneumonia. Conclusion Patients with lymphoma are at high risk for developing pneumonia after SARS-CoV-2 infection and suffer from prolonged symptoms. More aggressive vaccination and protective measures for patients with lymphoma who have impaired humoral response related to rituximab maintenance therapy and hypogammaglobulinemia are needed.
Abstract
Background Although patients with lymphoma appear particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the clinical evolution of coronavirus disease 2019 (COVID-19) in a patient with lymphoid malignancies has been under-represented, especially in relation to chemo-, chemo-immunotherapy. Materials and Methods Among adult patients with lymphoma receiving treatment in a specialized lymphoma center at a 500-bed, university-affiliated hospital, we retrospectively reviewed the medical records of patients diagnosed with SARS-CoV-2 infection from January 2020 to April 2022. Results A total of 117 patients with a median age of 53 years were included. One hundred twelves (95.7%) were non-Hodgkin lymphoma. Eighty-six patients (73.5%) were on active chemotherapy and 9 were post stem cell transplant state. Sixty-one patients had more than one comorbidity and 29 had hypogammaglobulinemia. Thirty-four patients (29.1%) had never received a COVID-19 vaccine. During a median follow-up of 134 days, COVID-19 pneumonia developed in 37 patients (31.6%). Excluding three patients who died before the 30 days, 31 out of 34 patients had ongoing symptomatic COVID-19. Eleven patients (9.4%) had post COVID-19 lung condition that persisted 90 days after COVID-19 diagnosis. Overall mortality was 10.3% (12 of 117), which was higher in patients with pneumonia. In multivariate analyses, age 65 years or older, follicular lymphoma, receiving rituximab maintenance therapy, and lack of vaccination were significantly associated with the development of COVID-19 pneumonia. Conclusion Patients with lymphoma are at high risk for developing pneumonia after SARS-CoV-2 infection and suffer from prolonged symptoms. More aggressive vaccination and protective measures for patients with lymphoma who have impaired humoral response related to rituximab maintenance therapy and hypogammaglobulinemia are needed.
참고문헌 (20)
- Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
- Lee J, "Lymphopenia as a biological predictor of outcomes in COVID-19 patients : a nationwide cohort study", Cancers(Basel), 13, pp.471~ (2021)
- Williamson EJ, "Factors associated with COVID-19-related death using OpenSAFELY", Nature, 584, pp.430~436 (2020)
- Kuderer NM, "Clinical impact of COVID-19 on patients with cancer(CCC19) : a cohort study", Lancet, 395, pp.1907~1918 (2020)
- Pagano L, "COVID-19 infection in adult patients with hematological malignancies : a European Hematology Association Survey(EPICOVIDEHA)", J Hematol Oncol, 14, pp.168~ (2021)
- Yasuda H, "Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma", Clin Lymphoma Myeloma Leuk, 20, pp.774~776 (2020)
- Taha Y, "Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency : successful clearance following combination casirivimab and imdevimab(REGN-COV2)monoclonal antibody therapy", Ann Clin Microbiol Antimicrob, 20, pp.85~ (2021)
- Nakajima Y, "Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient", J Infect Chemother, 27, pp.387~389 (2021)
- Levi G, "Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma", Monaldi Arch Chest Dis, 91, pp.1867~ (2021)
- Tarhini H, "Long-term severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infectiousness among three immunocompromised patients : from prolonged viral shedding to SARS-CoV-2 superinfection", J Infect Dis, 223, pp.1522~1527 (2021)
- Moran E, "Persistent SARS-CoV-2 infection : the urgent need for access to treatment and trials", Lancet Infect Dis, 21, pp.1345~1347 (2021)
- Kim Y, "Preliminary guidelines for the clinical evaluation and management of long COVID", Infect Chemother, 54, pp.566~597 (2022)
- "Korean COVID-19 living guideline"[URL]
- Bazdyrev E, "The hidden pandemic of COVID-19-induced organizing pneumonia", Pharmaceuticals(Basel), 15, pp.1574~ (2022)
- Duléry R, "Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy", Am J Hematol, 96, pp.934~944 (2021)
- Assanto GM, "Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19 : A retrospective study", Hematol Oncol, 41, pp.343~353 (2023)
- Chien KS, "Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies", Blood Adv, 7, pp.5691~5697 (2023)
- Liebers N, "Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients", Blood, 139, pp.142~147 (2022)
- Vijenthira A, "Outcomes of patients with hematologic malignancies and COVID-19 : a systematic review and meta-analysis of 3377 patients", Blood, 136, pp.2881~2892 (2020)
- Hong H, "Clinical characteristics and outcome of post COVID-19 lung conditions in patients with lymphoma", Infect Chemother, 55(Suppl 2), pp.S336~ (2023)